Resume de l’article : Obésité: le médicament Wegovy fourni à titre gracieux et transitoire à 3.000 patients en France

Article: « Obesity: the Wegovy drug provided free of charge and temporarily to 3,000 patients in France »

Answer:

* The drug Wegovy is being provided free of charge and temporarily to 3,000 patients in France as part of a program to combat obesity.
* Wegovy is a semaglutide-based medication that has been shown to be effective in promoting weight loss.
* The program is being run by the French National Healthcare System (CNAM) in collaboration with the drug’s manufacturer, Novo Nordisk.
* Patients who are eligible for the program must have a body mass index (BMI) of 30 or above, or a BMI of 27 or above with at least one associated health condition, such as type 2 diabetes or high blood pressure.
* The program will last for one year, during which time patients will receive weekly injections of Wegovy and participate in regular follow-up appointments with their healthcare providers.
* The goal of the program is to evaluate the effectiveness and safety of Wegovy in a real-world setting, and to gather data on the drug’s long-term impact on patients’ health and quality of life.